Cellectis Achieves Breakthrough Non-Viral Gene Insertion in Stem Cells
Cellectis SA has achieved a breakthrough in non-viral gene editing for hematopoietic stem and progenitor cells (HSPCs) using circular single-stranded DNA (CssDNA). This method demonstrated 3-5 times higher knock-in efficiency than linear single-stranded DNA (LssDNA), with rates exceeding 40%. CssDNA also enabled gene insertion at multiple loci and showed better engraftment and gene edit retention in murine models compared to viral vectors. The research is published in Nature Communications.
Cellectis SA has published new research results in Nature Communications demonstrating a highly efficient non-viral gene editing process for hematopoietic stem and progenitor cells (HSPCs). The study establishes that circular single-stranded DNA (CssDNA) serves as a superior DNA donor template for gene insertion, achieving 3-5 times higher knock-in efficiency than linear single-stranded DNA (LssDNA), with rates exceeding 40%. CssDNA was also shown to enable gene insertion at multiple loci and is applicable to other therapeutic cell types, such as primary T cells. Additionally, CssDNA-edited HSPCs exhibited better engraftment and gene edit retention in murine models compared to those edited with viral vectors. These results have already been published and are available on the Nature Communications website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9578656-en) on November 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
